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Back in August, the silicon equipment
manufacturers association SEMI (whose
co-founder, Bill Hugle, sadly died in
October) quietly slipped SiGe, GaAs and
InP under its arm and into its future silicon
road map, slotting these compounds into
the new wireless communications chapter.
SEMI might have made the first move, but
it is now followed in Europe by silicon's
premiere research laboratory IMEC. For
many in the compound industry, IMEC
probably has a low profile. Based in
Leuven, Belgium, IMEC was established in
1984 by the state government as a non-
profit organisation with an initial invest-
ment of 63m and a staff of 70. Working
quietly through strategic partnerships on
all aspects in the development of silicon,
chips and memory, initially with European
fabs and equipment manufacturers, it has
now grown to offices in California and
Shanghai and  Japanese representation. 
It is the largest independent silicon R&D
centre in Europe, and with its budget of
145m owes only 34m to a government
grant. The staff number 1,300 and the col-
laborators around 500.
At its October annual meeting to discuss
developments and look at the future,
IMEC president and CEO, Gilbert Declerck
announced that the mission for sub45nm
CMOS would involve advanced materials,
process steps and modules as well as
novel device concepts ‘beyond classical
CMOS.’  Silicon’s potential brick wall is
now causing IMEC programmes to draw
on Germanium CMOS based devices
(SiGe); epitaxial growth of AlGaN/GaN
HEMT amplifiers as well as InGaP and
GaAs (for the photovoltaic needs of the
European Space Agency).
What's so interesting is there are two dis-
tinct levels of activity.  The main action is
seen as IMEC’s first five core partners in
sub45nm research.  Infineon, Intel, Philips,
Samsung and STMicroelectronics are co-
funding and participating in programmes
“ranging from 1.5m to 500,000-
600,000.”  They  may be joined by
another three to five players. The major
activity will move from the 200mm wafer
line to the new 300mm line in rising new
buildings to be completed in 2004 (build-
ing and infra-structure cost 84m and
several 100m worth of equipment).
Meanwhile the modest future brick-wall
beaters, with very little pomp have had
their MOVPE equipment, formerly located
at Ghent, moved into laboratories at
IMEC's Leuven site, close to the 200mm
line and compound work goes on. 
It’s a breathtaking thought - small sub 6”
wafer production in the shadow of the
200mm and piazza size 300mm wafers.
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